Blog
RSS FeedPosted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 10 Jul 2022
PBAC recommendation for amendments to COVID-19 oral treatment restrictions
10 July 2022 - The PBAC recommended changes to the PBS eligibility criteria for both molnupiravir (Lagevrio) and nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 17 Jun 2022
Outcomes of the May 2022 PBAC intracycle meeting
17 June 2022 - The outcomes from the May 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 05 May 2022
Insights from the March 2022 PBAC meeting (part 4)
5 May 2022 - The apparent high recommendation rate for the March 2022 meeting does have some downsides. ...
Posted by Michael Wonder on 28 Apr 2022
Insights from the March 2022 PBAC meeting (part 3)
29 April 2022 - Wegovy was the first discrete medicine to have a stakeholder meeting before its consideration by the ...
Posted by Michael Wonder on 27 Apr 2022
Insights from the March 2022 PBAC meeting (part 2)
28 April 2022 The rejection of dostarlimab should not come as a surprise, the rejection of sotorsaib less so. ...
Posted by Michael Wonder on 26 Apr 2022
Insights from the March 2022 PBAC meeting (part 1)
26 April 2022 - Yesterday, we noted a recommendation rate of 78% which the highest value we have recorded since ...
Posted by Michael Wonder on 23 Apr 2022
Recommendations made by the PBAC - March 2022
22 April 2022 - The recommendations from the March 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 28 Feb 2022
New treatment for Australians with rare blood disease
28 February 2022 - Australians with paroxysmal nocturnal haemoglobinuria—a condition that produces defective blood cells—will have access to a new treatment ...
Posted by Michael Wonder on 25 Feb 2022
PBAC recommendation for molnupiravir (Lagevrio)
25 February 2022 - The PBAC undertook an expedited consideration of a sponsor submission (MSD) to add molnupiravir (Lagevrio) to the ...
Posted by Michael Wonder on 01 Feb 2022
'Lifesaving' cystic fibrosis drug Trikafta recommended for inclusion on PBS
1 February 2022 - Thousands of people with cystic fibrosis are one step closer to accessing a 'lifesaving' drug, after ...
Posted by Michael Wonder on 28 Jan 2022
Recommendations made by the PBAC – December 2021 intracycle meeting
28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 17 Dec 2021
Medicine agency recommends listing of life-saving drugs for Australian men with deadly forms of prostate cancer
17 December 2021 - Prostate Cancer Foundation of Australia has welcomed recommendations by Australia’s Pharmaceutical Benefits Advisory Committee to list ...
Posted by Michael Wonder on 17 Dec 2021
Recommendations made by the PBAC - November 2021
17 December 2021 - The recommendations from the November 2021 PBAC meeting are now available. ...